Ad is loading...
GGHSX
Price
$40.26
Change
-$1.01 (-2.45%)
Updated
Nov 15 closing price
PRHSX
Price
$92.58
Change
-$3.07 (-3.21%)
Updated
Nov 15 closing price
Ad is loading...

GGHSX vs PRHSX

Header iconGGHSX vs PRHSX Comparison
Open Charts GGHSX vs PRHSXBanner chart's image
Invesco Health Care R6
Price$40.26
Change-$1.01 (-2.45%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Health Sciences
Price$92.58
Change-$3.07 (-3.21%)
VolumeN/A
CapitalizationN/A
GGHSX vs PRHSX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GGHSX vs. PRHSX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GGHSX is a StrongSell and PRHSX is a StrongSell.

FUNDAMENTALS
Fundamentals
PRHSX has more cash in the bank: 14.1B vs. GGHSX (1.27B). GGHSX (0.00) and PRHSX (0.00) have matching dividends . GGHSX was incepted earlier than PRHSX: GGHSX (8 years) vs PRHSX (29 years). GGHSX is a more actively managed with annual turnover of: 59.00 vs. PRHSX (48.40). PRHSX has a lower initial minimum investment than GGHSX: PRHSX (2500) vs GGHSX (1000000). GGHSX annual gain was more profitable for investors over the last year : 14.25 vs. PRHSX (8.87). PRHSX return over 5 years is better than : 14.53 vs. GGHSX (-1.08).
GGHSXPRHSXGGHSX / PRHSX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years29 years-
Gain YTD7.4175.324139%
Front LoadN/AN/A-
Min. Initial Investment1000000250040,000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.27B14.1B9%
Annual Yield % from dividends0.000.00-
Returns for 1 year14.258.87161%
Returns for 3 years-21.40-18.20118%
Returns for 5 years-1.0814.53-7%
Returns for 10 yearsN/A24.78-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UEC7.420.06
+0.82%
Uranium Energy Corp
LKQ38.20-0.49
-1.27%
LKQ Corp
DRD9.23-0.19
-2.02%
DRDGOLD Ltd
LCTX0.86-0.02
-2.33%
Lineage Cell Therapeutics
EYEN0.10-0.23
-70.04%
Eyenovia